Bernstein Adjusts Moderna Price Target to $28 From $39, Maintains Market Perform Rating
Novavax Stock Is Up Again on Speculation Over the Fate of Its Covid Shot -- Barrons.com
HSBC Upgrades Moderna(MRNA.US) to Buy Rating, Cuts Target Price to $49
Will the US Stock Market's Rebound Ignite Your Next Trade?
Express News | Moderna : HSBC Cuts Target Price to $49 From $58
Notable Healthcare Headlines for the Week: Merck, Roche and Bausch Health in Focus
No Misses Here: Healthcare Earnings Sweep Past Wall Street Estimates
Earnings Week Ahead: MSFT, AAPL, META, AMZN, QCOM, PFE, MA, V, PYPL, ROKU, MCD, SBUX, KO, and More
The Trump administration plans to impose tariffs on imported Pharmaceuticals, and the U.S. Pharmaceutical Industry warns that it may increase drug costs.
A report commissioned by a trade organization in the USA Pharmaceutical Industry indicates that if the USA imposes a 25% tariff on imported Pharmaceuticals, it could increase the annual Pharmaceutical costs in the USA by nearly 51 billion dollars and raise drug prices by up to 12.9%.
Earnings Preview: Moderna to Report Financial Results Pre-market on May 01
Novavax Told by FDA to Conduct Additional Study for COVID Vaccine - Report
Moderna Options Spot-On: On April 25th, 99,736 Contracts Were Traded, With 783.64K Open Interest
Express News | Moderna Shares Lose Ground With Volume Spick in Late Afternoon, Last Down 2%; Pfizer Shares Lose Some Steam, Last up 0.6%
Moderna (NasdaqGS:MRNA) Sees 11% Share Price Surge Over Last Week
Options Market Statistics: Strong AI Data Center Demand Boosts NVIDIA Stock; Options Pop
Moderna Options Spot-On: On April 24th, 79,627 Contracts Were Traded, With 771.34K Open Interest
BofA Securities Maintains Moderna(MRNA.US) With Sell Rating, Cuts Target Price to $26
Unusual Options Activity: CMG, MRNA and Others Attract Market Bets, CMG V/OI Ratio Reaches 254.9
SK Bioscience Wins Patent Dispute Against Moderna Over MRNA Technology in South Korea
Moderna Options Spot-On: On April 23rd, 78,125 Contracts Were Traded, With 771.89K Open Interest